Abarca Forward Conference forges strategies for adopting AI and transformative models in healthcare
Abarca Forward Conference forges strategies for adopting AI and transformative models in healthcare
PR Newswire
SAN JUAN, Puerto Rico, March 27, 2024
Healthcare and technology leaders discussed and debated necessary changes for industry evolution, including the role of pharmacies, GLP-1s, and price transparency.
SAN JUAN, Puerto Rico, March 27, 2024 /PRNewswire/ -- Abarca, a pharmacy benefit manager (PBM) transforming the industry with a new approach to technology and business practices, brought healthcare and technology leaders together at the third annual Abarca Forward Conference to discuss, co-create, and debate how to create a better care experience for everyone.
"The healthcare landscape is undergoing a transformation," said Jason Borschow, president and CEO at Abarca. "The industry needs to find ways to accelerate this progress and make healthcare more seamless, personalized, and convenient for everyone. And that's what we're solving for at Abarca Forward."
This year, Abarca Forward offered an in-depth exploration of AI in pharmacy benefit management. This included a co-creation session led by Microsoft and Xtillion that enabled attendees to experience the capabilities of AI in real time. Additional sessions explored the forces that are changing the healthcare landscape today, including GLP-1s, the evolving role of pharmacies, and price clarity around prescriptions.
"To deliver the kind of seamless and personalized care experiences worthy of our family and friends, the healthcare industry needs to embrace change and think boldly about the future," said Alison Lum, vice president of Pharmacy Services at Blue Shield of California. "It was great to have the opportunity to come together to discuss new ways to accelerate transformation in order to provide cost clarity, better care, and greater value to every American."
The event featured speakers from leading national healthcare and technology organizations, including Blue Shield of California, Blue Cross of Idaho, Evio Pharmacy Solutions, FRESH Medicine, Gemini Health, GoodRx, Medtronic, PerformRx, Walgreens, and Welldoc.
"Given the advances in technology, clinical care, and business models, the industry today has an opportunity to finally overcome some of the greatest challenges in our healthcare system," concluded Borschow.
To learn more about Abarca Forward, visit www.abarcaforward.com.
About Abarca Health
At Abarca, we see a future in which healthcare is seamless and personalized, and we are working every day to make it a reality for the people and organizations we serve. We are starting with prescriptions, the frontline of healthcare. But, leveraging our smarter technology, straightforward approach to business, and a team that is driven to innovate and find a better way in everything we do, we are enabling a broader healthcare revolution. Abarcahealth.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/abarca-forward-conference-forges-strategies-for-adopting-ai-and-transformative-models-in-healthcare-302101320.html
SOURCE Abarca
-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing